These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9496386)

  • 1. A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study.
    Fountzilas G; Athanassiades A; Giannakakis T; Briasoulis E; Bafaloukos D; Kalogera-Fountzila A; Onienaoum A; Kalofonos H; Pectasides D; Andreopoulou E; Bamia C; Kosmidis P; Pavlidis N; Skarlos D
    Ann Oncol; 1997 Dec; 8(12):1213-20. PubMed ID: 9496386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.
    Bastholt L; Dalmark M; Gjedde SB; Pfeiffer P; Pedersen D; Sandberg E; Kjaer M; Mouridsen HT; Rose C; Nielsen OS; Jakobsen P; Bentzen SM
    J Clin Oncol; 1996 Apr; 14(4):1146-55. PubMed ID: 8648369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group.
    Fountzilas G; Papadimitriou C; Dafni U; Bafaloukos D; Skarlos D; Moulopoulos LA; Razis E; Kalofonos HP; Aravantinos G; Briassoulis E; Papakostas P; Abela K; Gogas E; Kosmidis P; Pavlidis N; Dimopoulos MA
    J Clin Oncol; 2001 Apr; 19(8):2232-9. PubMed ID: 11304776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group.
    Brufman G; Colajori E; Ghilezan N; Lassus M; Martoni A; Perevodchikova N; Tosello C; Viaro D; Zielinski C
    Ann Oncol; 1997 Feb; 8(2):155-62. PubMed ID: 9093724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose epirubicin and r-met-hu G-CSF (filgrastim) in the treatment of patients with advanced breast cancer: A Hellenic Cooperative Oncology Group study.
    Fountzilas G; Skarlos D; Katsohis C; Pavlidis N; Giannakakis T; Bafaloukos D; Fahantidis E; Klouvas G; Beer M; Kosmidis P
    Med Pediatr Oncol; 1995 Jan; 24(1):23-8. PubMed ID: 7526143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study.
    Nielsen D; Dombernowsky P; Larsen SK; Hansen OP; Skovsgaard T
    Cancer Chemother Pharmacol; 2000; 46(6):459-66. PubMed ID: 11138459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial.
    Joensuu H; Holli K; Heikkinen M; Suonio E; Aro AR; Hietanen P; Huovinen R
    J Clin Oncol; 1998 Dec; 16(12):3720-30. PubMed ID: 9850014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer.
    Razis E; Dimopoulos AM; Bafaloukos D; Papadimitriou C; Kalogera-Fountzila A; Kalofonos H; Briassoulis E; Samantas E; Keramopoulos A; Pavlidis N; Kosmidis P; Fountzilas G
    Cancer Invest; 2001; 19(2):137-44. PubMed ID: 11296618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
    Ryberg M; Nielsen D; Skovsgaard T; Hansen J; Jensen BV; Dombernowsky P
    J Clin Oncol; 1998 Nov; 16(11):3502-8. PubMed ID: 9817267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.
    Gogas H; Dafni U; Karina M; Papadimitriou C; Batistatou A; Bobos M; Kalofonos HP; Eleftheraki AG; Timotheadou E; Bafaloukos D; Christodoulou C; Markopoulos C; Briasoulis E; Papakostas P; Samantas E; Kosmidis P; Stathopoulos GP; Karanikiotis C; Pectasides D; Dimopoulos MA; Fountzilas G
    Breast Cancer Res Treat; 2012 Apr; 132(2):609-19. PubMed ID: 22187126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancer.
    Scinto AF; Ferraresi V; Campioni N; Tonachella R; Piarulli L; Sacchi I; Giannarelli D; Cognetti F
    Ann Oncol; 1995 Sep; 6(7):665-71. PubMed ID: 8664187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer.
    Lalisang RI; Wils JA; Nortier HW; Burghouts JT; Hupperets PS; Erdkamp FL; Schouten HC; Blijham GH
    J Clin Oncol; 1997 Apr; 15(4):1367-76. PubMed ID: 9193328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
    Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
    Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
    Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer.
    Nisticò C; Garufi C; Barni S; Frontini L; Gallà DA; Giannarelli D; Vaccaro A; D'Ottavio AM; Terzoli E
    Ann Oncol; 1999 Aug; 10(8):937-42. PubMed ID: 10509155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
    ; Basser RL; O'Neill A; Martinelli G; Green MD; Peccatori F; Cinieri S; Coates AS; Gelber RD; Aebi S; Castiglione-Gertsch M; Viale G; Price KN; Goldhirsch A
    J Clin Oncol; 2006 Jan; 24(3):370-8. PubMed ID: 16421418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epirubicin-containing high-dose chemotherapy followed by autologous hematopoietic progenitor cell transfusion for patients with chemotherapy-sensitive metastatic breast cancer: results of 5-year follow-up.
    Ito Y; Mukaiyama T; Ogawa M; Mizunuma N; Takahashi S; Aiba K; Horikoshi N
    Cancer Chemother Pharmacol; 1999; 43(1):8-12. PubMed ID: 9923535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexrazoxane cardioprotection in advanced breast cancer patients undergoing high-dose epirubicin treatment.
    Vici P; Ferraironi A; Di Lauro L; Carpano S; Conti F; Belli F; Paoletti G; Maini CL; Lopez M
    Clin Ter; 1998; 149(921):15-20. PubMed ID: 9621483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.
    Bonnefoi H; Biganzoli L; Cufer T; Mauriac L; Hamilton A; Schaefer P; Piccart M
    Breast Cancer Res Treat; 2001 Nov; 70(1):55-63. PubMed ID: 11768362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.